$1,000.00
Lorem ipsum dolor sit amet consectetur. Enim sit felis eget eros nisi facilisis sem amet.
a day is all it takes to support long-term eye health.
waveform technology to maximize effectiveness while keeping eyes safe.
of patients showed measurable improvement after treatment.
improved by at least 10 letters on the EDTRS vision chart.
Invizion is a patented, non-invasive headset that delivers gentle microcurrents across closed eyelids to stimulate retinal cells and support visual improvement — without surgery or drugs.
Invizion is designed for adults diagnosed with Age-related Macular Degeneration (AMD) or other conditions that affect central vision and retinal health.
The device’s patented waveform gently activates Retinal Pigment Epithelium (RPE) cells, boosting mitochondrial energy (ATP) and helping clear macular waste for improved eye function.
Yes. Invizion therapy is completely pain-free and non-invasive. It involves no injections, light exposure, or systemic drugs — and has shown measurable improvement in clinical studies.
Typical treatment involves 30-minute sessions over 10 days, with noticeable improvement often seen within that period. Your eye-care professional may adjust your schedule as needed.
Currently, no at-home microcurrent therapy device for macular degeneration has received full FDA clearance. Invizion is actively pursuing regulatory approval following its successful European launch.
Inizion uses controlled light stimulation to target the retina’s energy centers. These sessions are designed to improve mitochondrial activity in retinal cells — helping them function more efficiently and resist degeneration. The result: a clearer, more comfortable visual experience that supports long-term macular wellness.

Founder and visionary behind Invizion’s breakthrough microcurrent therapy technology.

Leads global growth, bringing Invizion’s technology to patients and providers worldwide.

Lorem ipsum dolor sit amet consectetur. Nulla vitae convallis,

Lorem ipsum dolor sit amet consectetur. Nulla vitae convallis,